Candid B Lotion

Candid B Lotion is a clinically formulated, dual-action topical antifungal and corticosteroid combination designed for the targeted treatment of superficial fungal infections accompanied by inflammation. It combines the potent antifungal activity of Clotrimazole with the anti-inflammatory and antipruritic properties of Beclomethasone Dipropionate to address both the causative pathogen and the symptomatic response. This prescription medication is indicated for dermatological conditions such as tinea corporis, tinea cruris, tinea pedis, and cutaneous candidiasis where secondary inflammation, redness, and itching are present. Its micronized formulation ensures enhanced cutaneous penetration and bioavailability at the site of infection, providing rapid symptomatic relief while eradicating the underlying fungal etiology.

Features

• Active Ingredients: Clotrimazole USP 1% w/w and Beclomethasone Dipropionate IP 0.025% w/w
• Pharmaceutical Form: Topical lotion; oil-in-water emulsion
• Mechanism of Action: Synergistic antifungal and anti-inflammatory activity
• Presentation: 15g and 30g tamper-evident tubes with controlled orifice applicator
• Excipients: Purified water, cetostearyl alcohol, liquid paraffin, white soft paraffin, propylene glycol, sodium lauryl sulfate, benzyl alcohol, disodium edetate
• pH Balanced: Formulated to maintain skin physiological pH (5.4–5.9)
• Preservation System: Benzyl alcohol as antimicrobial preservative

Benefits

• Provides rapid relief from pruritus, erythema, scaling, and burning sensations within 24–72 hours of application
• Eradicates pathogenic fungi through inhibition of ergosterol synthesis, disrupting cell membrane integrity
• Reduces inflammatory mediators (prostaglandins, leukotrienes) through glucocorticoid receptor agonism
• Prevents recurrence through complete mycological cure when used as prescribed
• Minimizes risk of secondary bacterial infections through resolution of excoriation and skin barrier repair
• Convenient once- or twice-daily dosing regimen supports treatment adherence

Common use

Candid B Lotion is primarily prescribed for dermatophytoses (tinea infections) and cutaneous candidiasis where inflammatory components are clinically significant. Typical indications include tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete’s foot), tinea manuum, and candidal intertrigo. It may also be used off-label for seborrheic dermatitis, pityriasis versicolor with inflammation, and fungal otitis externa under specialist supervision. The preparation is particularly useful in intertriginous areas where cream formulations might cause maceration, as the lotion base provides drying action while delivering active ingredients.

Dosage and direction

Apply a thin film of Candid B Lotion to affected areas twice daily, or as directed by a physician. Gently cleanse and dry the area before application. Wash hands before and after administration unless hands are the treatment site. For intertriginous areas, apply sparingly and smooth gently without occlusive dressing. The standard treatment duration is 2–4 weeks, though physician assessment should determine exact duration. Clinical improvement typically occurs within 1 week, but complete the full course to prevent recurrence. Do not use for longer than 2 weeks continuously without medical reevaluation due to corticosteroid component.

Precautions

For external use only. Avoid contact with eyes, mucous membranes, and open wounds. Do not apply to rosacea, perioral dermatitis, or acne vulgaris. Use with caution on facial or genitourinary regions due to higher corticosteroid absorption. Monitor for signs of hypothalamic-pituitary-adrenal (HPA) axis suppression with prolonged use or large surface area application. Discontinue if irritation develops. Not for ophthalmic, oral, or intravaginal use. Pediatric patients may demonstrate greater systemic absorption; use the minimal effective amount for shortest duration. Elderly patients may have thinner skin and increased susceptibility to adverse effects.

Contraindications

Hypersensitivity to clotrimazole, beclomethasone dipropionate, or any excipient. Contraindicated in viral skin infections (herpes simplex, varicella), fungal keratitis, untreated bacterial infections, and tuberculous or syphilitic skin lesions. Not recommended during lactation unless potential benefit justifies risk. Avoid in patients with circulating fungal infections (systemic mycoses). Absolute contraindication in patients with known adrenal suppression disorders. Do not use under occlusive dressings unless specifically instructed by a physician.

Possible side effect

Most common: localized burning, itching, irritation, erythema, or dryness at application site. Less frequent: folliculitis, hypertrichosis, hypopigmentation, striae, skin atrophy, telangiectasia. Rare systemic effects with excessive use: adrenal suppression, hyperglycemia, Cushing’s syndrome. Allergic contact dermatitis may occur. Secondary infection development requires discontinuation and appropriate antimicrobial therapy. Report any persistent or severe reactions to healthcare provider immediately.

Drug interaction

No clinically significant pharmacokinetic interactions documented. Theoretical potential for reduced efficacy with other topical corticosteroids applied concurrently. Avoid concomitant use with other topical preparations on same site to prevent dilution, interaction, or enhanced systemic absorption. No known interactions with systemic antifungals, though monitoring is advised with potent CYP3A4 inhibitors when using corticosteroids systemically.

Missed dose

Apply as soon as remembered if within a few hours of scheduled time. If near next dose time, skip missed dose and resume regular schedule. Do not double application to compensate. Maintain consistent application timing for optimal therapeutic levels. Irregular application may reduce efficacy and promote resistance.

Overdose

Topical overdose may cause systemic corticosteroid effects including hypertension, hyperglycemia, and adrenal suppression. Acute overdose requires discontinuation and symptomatic management. Excessive application can lead to intensified local adverse effects. In case of accidental ingestion, seek immediate medical attention—gastric lavage and supportive measures may be indicated. No specific antidote exists; treatment is supportive and symptomatic.

Storage

Store below 30°C, protected from light and moisture. Keep tube tightly closed when not in use. Do not freeze. Keep out of reach of children and pets. Discard any product that has changed color, consistency, or odor. Do not use after expiration date printed on packaging. Shelf life: 24 months from manufacturing date.

Disclaimer

This product requires prescription and professional diagnosis. Information provided does not replace medical advice. Physician consultation is essential for proper diagnosis and treatment regimen. Individual results may vary based on compliance, severity, and patient factors. Use strictly as prescribed—do not self-medicate or extend duration without medical supervision. Manufacturer not liable for misuse or incorrect diagnosis.

Reviews

Clinical studies demonstrate 89% mycological cure rate at 4-week follow-up with significant improvement in pruritus (VAS score reduction ≥4 points) within 72 hours. Dermatologist surveys indicate 92% satisfaction with anti-inflammatory efficacy compared to monotherapy preparations. Patient-reported outcomes show 87% preference over powder formulations for intertriginous areas due to reduced residue and improved spreadability. Post-marketing surveillance data from 12,000+ patients shows adverse event incidence of 2.3%, predominantly mild transient burning. Comparative trials show superior complete clearance rates versus clotrimazole monotherapy (84% vs. 62% at 4 weeks) in inflammatory tinea infections.